Form 8-K

8-K — Onconetix, Inc.

Accession: 0001213900-26-034902

Filed: 2026-03-27

Period: 2026-03-23

CIK: 0001782107

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0283569-8k_onconetix.htm (Primary)

EX-3.1 — CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, OF ONCONETIX, INC (ea028356901ex3-1.htm)

EX-99.1 — PRESS RELEASE, DATED MARCH 23, 2026 (ea028356901ex99-1.htm)

GRAPHIC (ea028356901_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0283569-8k_onconetix.htm · Sequence: 1

false

--12-31

0001782107

2026-03-23

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

March 23, 2026

Onconetix, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-41294

83-2262816

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

201 E. Fifth Street, Suite 1900

Cincinnati, Ohio

45202

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (513) 620-4101

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name

of each exchange on which registered

Common Stock, par value $0.00001 per share

ONCO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation

or Bylaws; Change in Fiscal Year.

previously reported on a Current Report on Form 8-K filed on February 9, 2026, Onconetix, Inc. (the “Company”) held a special

meeting of stockholders (the “Special Meeting”) on February 3, 2026. At the Special Meeting, the Company’s stockholders

approved the adoption and approval of an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate

of Incorporation, as amended to date (the “Charter”), to effect a reverse stock split of all of the outstanding shares of

its issued and outstanding common stock, par value $0.00001 (the “Common Stock”), at a ratio in the range of one-for-two (1:2)

to one-for-fifty (1:50) at any time prior to the one-year anniversary date of the Special Meeting, with such ratio to be determined by

the Board (the “Reverse Stock Split Proposal”),.

March 6, 2026, the Board determined to fix a reverse stock split ratio of its Common Stock of 1-to-5 (the “Reverse Stock Split”).

On March 24, 2026, the Company filed the Amendment to its Charter with the Secretary of State of the State of Delaware to effect the Reverse

Stock Split. The Reverse Stock Split became effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern Time on March

25, 2026 (the “Effective Time”). The Company’s Common Stock continues to trade on The Nasdaq Capital Market under the

symbol ONCO and has been trading on a split-adjusted basis since the market opened on March 25, 2026, under a new CUSIP number, 68237Q

302.

the Effective Time, every 5 (five) shares of the Company’s issued and outstanding Common Stock had converted automatically into

one (1) issued and outstanding share of Common Stock, with no corresponding reduction in the number of authorized shares of Common Stock,

and without any change in the par value per share. Stockholders holding shares through a brokerage account had their shares automatically

adjusted to reflect the 1-for-5 Reverse Stock Split. It was not necessary for stockholders holding shares of the Common Stock in certificated

form to exchange their existing stock certificates for new stock certificates of the Company in connection with the Reverse Stock Split,

although stockholders may do so if they wish.

The

Reverse Stock Split affected all stockholders uniformly and has not altered any stockholder’s percentage interest in the Company’s

equity, except to the extent that the Reverse Stock Split would have resulted in a stockholder owning a fractional share. No fractional

shares were issued in connection with the Reverse Stock Split. Stockholders who would have otherwise been entitled to receive a fractional

share will instead receive a cash payment (without interest) equal to such fraction multiplied by the closing sale price per share of

the Common Stock on The Nasdaq Capital Market at the close of business on the date prior to the effective date of the Reverse Stock Split,

or March 24, 2026 (with such closing sale price being adjusted to give effect to the Reverse Stock Split). The Reverse Stock Split reduced

the number of shares of Common Stock issued and outstanding from 3,464,686 to 692,927 shares. Proportional

adjustments were made to the number of shares of Common Stock issuable upon exercise or conversion of the Company’s equity awards,

convertible preferred stock and warrants, as well as the applicable exercise price. Stockholders with shares in brokerage accounts should

direct any questions concerning the Reverse Stock Split to their broker; all other stockholders may direct questions to the Company’s

transfer agent, Continental Stock Transfer & Trust Company, at 212-509-4000.

The

foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text

of the Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 8.01 Other Events.

March 23, 2026, the Company issued a press release announcing the Reverse Stock Split, a copy of which is filed as Exhibit 99.1 to this

Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed or furnished,

as applicable, with this Current Report on Form 8-K:

Exhibit No.

Description

3.1

Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc.

99.1

Press Release, dated March 23, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Onconetix, Inc.

March 26, 2026

By:

/s/ David Allan White

Name:

David Allan White

Title:

Chief Executive Officer

EX-3.1 — CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, OF ONCONETIX, INC

EX-3.1

Filename: ea028356901ex3-1.htm · Sequence: 2

Exhibit 3.1

CERTIFICATE OF AMENDMENT

OF CERTIFICATE OF INCORPORATION

OF ONCONETIX, INC.

Onconetix, Inc., a corporation organized and existing

under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows:

1. The name of the Corporation is Onconetix, Inc.

2. The Certificate of Incorporation of the Corporation

is amended by adding the following new paragraph to the end of Article IV, Section D:

6. Upon the filing and effectiveness

(the “Effective Time”) of this amendment to the Corporation’s Certificate of Incorporation, as amended,

pursuant to the Delaware General Corporation Law, each five (5) shares of the Common Stock issued immediately prior to the Effective Time

(the “Old Common Stock”) shall be reclassified and combined into one validly issued, fully paid and non-assessable

share of the Corporation’s Common Stock, $0.00001 par value per share (the “New Common Stock”), without

any action by the holder thereof (the “Reverse Stock Split”). No fractional shares of New Common Stock shall

be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Effective Time of a book entry position

which formerly represented shares of Old Common Stock that were issued and outstanding immediately prior to the Effective Time, any person

who would otherwise be entitled to a fractional share of New Common Stock as a result of the Reverse Stock Split, following the Effective

Time, shall be entitled to receive a cash payment equal to the fraction of a share of New Common Stock to which such holder would otherwise

be entitled multiplied by the closing price per share of the New Common Stock on The Nasdaq Stock Market LLC at the close of business

on the date prior to the Effective Time. Each book entry position that theretofore represented shares of Old Common Stock shall thereafter

represent that number of shares of New Common Stock into which the shares of Old Common Stock represented by such book entry position

shall have been reclassified and combined; provided, that each person holding of record a book entry position that represented shares

of Old Common Stock shall receive, a new book entry position evidencing and representing the number of shares of New Common Stock to which

such person is entitled under the foregoing reclassification and combination.

3. This Certificate of Amendment has been duly

adopted by the Board of Directors and stockholders of the Corporation in accordance with Section 242 of the General Corporation Law of

the State of Delaware.

4. This Certificate of Amendment shall become

effective as of 12:01 a.m., Eastern Time on March 25, 2026.

IN WITNESS WHEREOF, the Corporation has caused

this Certificate of Amendment to be duly executed in its corporate name as of the 24th day of March, 2026.

/s/ Karina M. Fedasz

Karina M. Fedasz

Interim Chief Financial Officer

EX-99.1 — PRESS RELEASE, DATED MARCH 23, 2026

EX-99.1

Filename: ea028356901ex99-1.htm · Sequence: 3

Exhibit 99.1

Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc.

(NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research,

development, and commercialization of innovative solutions for men’s health and oncology, today announced that its Board of Directors

(the “Board of Directors” or “Board”) has approved a 1-for-5 reverse stock split of its outstanding shares of

common stock, to be effective as of 12:01 a.m. Eastern Time on March 25, 2026.

On February 3, 2026, Onconetix held a special meeting of stockholders

(the “Special Meeting”), at which the Company’s stockholders approved a proposal to effect a reverse split, at a ratio

in the range of 1-for-2 to 1-for-50, at any time prior to the one-year anniversary date of the Special Meeting, with such ratio to be

determined by the Board without further approval or authorization of the stockholders. Since the receipt of such stockholder approval,

the Company’s Board of Directors has determined to fix a split ratio of 1-for-5 shares. The Company’s common stock will begin

trading on a reverse stock split-adjusted basis at the opening of the market on March 25, 2026. Following the reverse stock split, the

Company’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “ONCO” under the new CUSIP

number 68237Q 302. The reverse stock split is intended to enable the Company to maintain compliance with the minimum bid price requirement

of $1.00 per share of common stock for continued listing on The Nasdaq Capital Market.

At the effective time of the reverse split, every 5 issued and outstanding

shares of the Company’s common stock will be converted automatically into one share of the Company’s common stock without

any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split, and fractional

shares resulting from the reverse stock split will be canceled with the holders thereof receiving cash compensation. The amount of compensation

will be determined by multiplying the fractional share by the closing price per share of the Company’s common stock on The Nasdaq

Capital Market at the close of business on the trading day prior to the effective date of the reserve stock split, or March 24, 2026.

The reverse split will have no effect on the number of authorized shares of the Company’s common stock, and the ownership percentage

of each stockholder will remain unchanged other than as a result of fractional shares. The reverse stock split will additionally apply

to the Company’s common stock issuable upon exercise or conversion of the Company’s equity awards, convertible preferred stock

and warrants, as well as the applicable exercise price.

The reverse stock split will reduce the number of outstanding shares

of the Company’s common stock from approximately 3.6 million to approximately 0.7 million.

About Onconetix, Inc.

Onconetix (Nasdaq: ONCO) is a commercial stage biotechnology company

focused on the research, development and commercialization of innovative solutions for men’s health and oncology. Onconetix owns

Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European

Union (“EU”) under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test (“LDT”)

through its license agreement with Labcorp. For more information, visit www.onconetix.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within

the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking

words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and

“intend,” among others. These forward-looking statements (including, without limitation, statements regarding the timing and

effectiveness of the anticipated reverse split and compliance with applicable Nasdaq continued listing requirements) are based on Onconetix’s

current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ

materially from those indicated by such forward-looking statements. These factors include, but are not limited to, market and other conditions;

our ability to comply with the continued listing requirements of, and remain trading on, the Nasdaq Stock Market, LLC; our

ability to consummate the transaction on a timely basis as contemplated by the Share Exchange Agreement with Realbotix, LLC (“Realbotix”

and the “Share Exchange Agreement” and the transactions contemplated therein, the “Realbotix Transaction”) and

the anticipated benefits of the Realbotix Transaction; our ability to complete the Realbotix Transactions on the same term

as contemplated in the Share Exchange Agreement; our ability to successfully integrate our business and Realbotix’s

business in the expected timeframe; risks related to unexpected market disruptions that may cause major losses to us not anticipated under

the Share Exchange Agreement; risks related to pending Realbotix Transactions that may divert the attention of our management; the failure

to obtain and maintain the necessary regulatory approvals to market and commercialize Onconetix’s products; risks related to the

Company’s ability to obtain and maintain intellectual property protection for its current products; and the Company’s reliance

on third parties, including manufacturers and logistics companies. As with any commercial-stage pharmaceutical product or any product

candidate under clinical development, there are significant risks in the development, regulatory approval and commercialization of biotechnology

products. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk

factors set forth in Onconetix’s Annual Report on Form 10-K, filed with the SEC on March 13, 2026 and periodic reports filed with

the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors

and other cautionary statements. The information set forth herein speaks only as of the date thereof.

For more information:

Onconetix, Inc.

201 E. Fifth Street, Suite 1900

Cincinnati, OH 45202

Phone: (513) 620-4101

Investor Contact Information:

Onconetix Investor Relations

Email: investors@onconetix.com

GRAPHIC

Filename: ea028356901_ex99-1img1.jpg · Sequence: 4

Binary file (3633 bytes)

Download ea028356901_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Mar. 23, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 23, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-41294

Entity Registrant Name

Onconetix, Inc.

Entity Central Index Key

0001782107

Entity Tax Identification Number

83-2262816

Entity Incorporation, State or Country Code

Entity Address, Address Line One

201 E. Fifth Street

Entity Address, Address Line Two

Suite 1900

Entity Address, City or Town

Cincinnati

Entity Address, State or Province

Entity Address, Postal Zip Code

45202

City Area Code

513

Local Phone Number

620-4101

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.00001 per share

Trading Symbol

ONCO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration